The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Can daratumumab overcome the negative prognostic impact of high-risk cytogenetics?

Jun 22, 2020

During the 25th Congress of the European Hematology Association (EHA), the MM Hub spoke to Luciano Costa, University of Alabama at Birmingham, Birmingham, US. We asked: Can daratumumab (dara) overcome the negative prognostic impact of high-risk cytogenetics?

Dara has impacted the lives of patients with both newly diagnosed multiple myeloma (NDMM) and relapsed/refractory disease. However, the clinical activity of dara is yet to be determined in patients with NDMM and high-risk cytogenetics.

At this year's virtual EHA Annual Congress, results will be presented from a meta analysis of patients with high-risk cytogenetics treated in trials evaluating an MM backbone treatment ± dara. Here, Luciano Costa highlights the benefit of dara observed in this setting and other key results.

Can daratumumab overcome the negative prognostic impact of high-risk cytogenetics?